United States

Life sciences: IPO and public market update


In recent years, there has been an increasing number of life sciences initial public offerings (IPOs). More than 40% of all IPOs from 2016 through mid-2020 were in the life sciences industry, as compared with only 24% during the preceding 10-year period. On the heels of a record-breaking year in 2020, special-purpose acquisition company (SPAC) IPOs set a new record in January 2021 by raising nearly $26 billion in proceeds in a single month.

RSM US LLP recently shared insights around the public markets at the Informa Connects Finance and Accounting for Bioscience Companies conference. Check out the video clips below from this session to hear the latest on what’s driving this IPO trend and how you can prepare for going public.

Steve Kemler, life sciences senior analyst, provides an update on the public markets through the perspective of a biopharma on the road to IPO.

Chris Martin, life sciences technical accounting consulting lead, discusses how life sciences companies can best position themselves to access the markets when the opportunity arises.

You may also be interested in


IPO readiness: 5 questions life sciences companies should consider

How can life sciences companies looking to go public position themselves for success? It’s all about setting the stage early on.


Is a SPAC the right route for your organization?

SPACs have grown in popularity recently as a means of going public. Learn why Draft Kings decided on a SPAC merger.

  • January 11, 2021

Contact our specialists

See what we can do for your growing life sciences company